

DCAT[®]

TOP INDUSTRY NEWS

This Issue Sponsored By:

DCAT[®]
BENCH
MARKING

MANAGING BIO/PHARMA
SUPPLY CHAINS IN AN UNCERTAIN
GLOBAL TRADE ENVIRONMENT

SURVEY FIELDDED: FALL 2019 • RESULTS RELEASED: JAN. 2020

- ▶ **[President Trump Plans to Nominate New FDA Commissioner](#)**
President Trump plans to nominate Dr. Stephen Hahn, Chief Medical Executive, University of Texas MD Anderson Cancer Center, to be the next FDA Commissioner. [Read More >](#)
- ▶ **[Amgen, BeiGene in \\$2.7-Bn Oncology Pact for China](#)**
Amgen has formed a strategic oncology pact with BeiGene, a Beijing-based company, under which it will acquire a stake in BeiGene for \$2.7 billion. [Read More >](#)
- ▶ **[AstraZeneca To Create New R&D and AI Centers; \\$1-Bn Joint Fund in China](#)**
AstraZeneca is creating a new global R&D center and an AI innovation center in China and is partnering to establish a \$1-billion healthcare investment fund in China. [Read More >](#)
- ▶ **[Endo CEO To Step Down; Company Implements Succession Plan](#)**
Paul V. Campanelli, President and CEO of Endo International, a generics/specialty pharma company, is retiring, and the company is implementing a succession plan. [Read More >](#)
- ▶ **[Roche, Dicerna Form \\$1.67-Bn Deal for Hepatitis B Treatments](#)**
Roche has formed a research and licensing pact with Dicerna Pharmaceuticals, a developer of RNAi medicines, in a deal worth up to \$1.67 billion. [Read More >](#)
- ▶ **[Takeda To Divest Select Products to Stada in \\$660-Million Deal](#)**
As part of a plan to divest non-core assets after its \$62-billion acquisition of Shire, Takeda has agreed to divest 20 select products to Stada for \$660 million. [Read More >](#)
- ▶ **[Sandoz Receives FDA Approval for Biosimilar of Amgen's Neulasta](#)**
Novartis' Sandoz has received FDA approval for a biosimilar version of Amgen's blockbuster drug, Neulasta (pegfilgrastim). [Read More >](#)
- ▶ **[Bayer Completes \\$585-M Sale of Dr. Scholl's to Investment Firm](#)**
Bayer has completed the sale of its Dr. Scholl's consumer footcare business to Yellow Wood Partners for \$585 million. [Read More >](#)
- ▶ **[Arranta Bio Launches as New CDMO; Partners with Thermo Fisher](#)**
Arranta Bio, a CDMO focused on the human microbiome, has completed an \$82-million funding round and formed a partnership with Thermo Fisher Scientific. [Read More >](#)
- ▶ **[Novartis Has Setback for Gene Therapy Zolgensma](#)**
The FDA has placed a partial clinical hold for intrathecal administration of Novartis' gene therapy, Zolgensma, which was earlier approved for intravenous use. [Read More >](#)
- ▶ **[Global Pharma Briefs: News from Europe and Asia](#)**
A roundup of developments and latest news from Germany (AstraZeneca, Takeda) and India (Zydus Cadila). [Read More >](#)



Top Industry News is published and distributed weekly to DCAT member companies, Visit www.dcat.org.

